Novo Nordisk (NVO. N) fell 26 percent in premarket trading after the company named a new CEO.

Disclaimer:

1. The information provided does not constitute investment advice. Investors should make independent decisions and bear all risks themselves.

2. The copyright of this content belongs to the original author. The views expressed herein are solely those of the author and do not represent the stance or position of this website.